A 31-year-old man is newly diagnosed with HIV and presents to a clinic 3 days later for initial evaluation. The pre-visit initial laboratory studies show a CD4 count of 573 cells/mm3 and an HIV RNA of 68,730 copies/mL. He has not received HIV preexposure prophylaxis (PrEP).
Which one of the following would you recommend regarding HIV drug-resistance testing?
Figure 1. Reversion of Transmitted Drug-Resistant HIV in the Absence of Antiretroviral Therapy
In the absence of antiretroviral selective pressure, some of the transmitted drug-resistant HIV may back mutate to wild-type HIV or simply be overpopulated by wild-type HIV. In this situation, the ability to detect these drug-resistant mutations on a standard genotype will diminish over time.
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
January 28th, 2025
January 28th, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant